What is pertuzumab used to treat?
PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin® (trastuzumab) and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer …
Who is eligible for PERJETA?
Neoadjuvant eligibility To begin PERJETA and Herceptin® (trastuzumab)-based therapy in the neoadjuvant setting, patients must have HER2+ breast cancer with locally advanced, inflammatory, or early stage breast cancer (either node-positive or tumor size >2 cm).
What drug class is pertuzumab?
Perjeta (pertuzumab) Injection is a prescription medicine used to treat the symptoms of Early Breast Cancer and Metastatic Breast Cancer. Perjeta may be used alone or with other medications. Perjeta belongs to a class of drugs called Antineoplastics, Anti-HER2; Antineoplastics, Monoclonal Antibody.
Is pertuzumab an immunotherapy?
Passive immunotherapy has provided several successful treatments for breast cancer. The current mainstay of passive immunotherapy includes trastuzumab, pertuzumab, and trastuzumab emtansine (T-DM1).
Does pertuzumab lower immune system?
Pertuzumab also causes heart failure, infusion reactions, and serious allergic reactions. Treatment may also reduce the number of red blood cells (anemia), and reduce the number of platelets and white blood cells. A reduced number of white blood cells increases the risk for febrile neutropenia and infections.
What are the side effects of pertuzumab?
The following side effects are common (occurring in greater than 30%) for patients taking Pertuzumab. Reactions reported in combination therapy with trastuzumab and docetaxel:
- Diarrhea.
- Hair loss.
- Low white blood cell count.
- Nausea.
- Fatigue.
- Rash.
- Peripheral neuropathy (numbness & tingling in hands and feet)
Is pertuzumab a chemo or immunotherapy?
Pertuzumab (Perjeta®) and trastuzumab are targeted therapy drugs used to treat breast cancer. They are usually given with chemotherapy.
How long does Perjeta stay in system?
Based on a population PK analysis of 481 patients, the median clearance (CL) of pertuzumab was 0.24 L/day and the median half-life was 18 days.
How long do you take pertuzumab?
The first dose of Perjeta is the largest and takes about an hour to complete. After that, it takes 30 to 60 minutes to get Perjeta, which is usually given every 3 weeks in a doctor’s office. Most people get Perjeta every 3 weeks for 18 to 25 months.
Is pertuzumab a chemo?
Pertuzumab is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug. This medication is classified as an “antineoplastic agent and a monoclonal antibody”.
What should I know about pertuzumab before taking it?
Important Information. Pertuzumab can cause birth defects or death to the unborn baby. Do not use if you are pregnant. Avoid getting pregnant while using pertuzumab and for at least 7 months after your last dose.
What are the indications for a hysterectomy in women with uterine disorders?
Apprpriate indications for hysterectomy include benign uterine disease and/or symptoms — dysfunctional uterine bleeding; uterine pain, bleeding, and enlargement; uterine descensus and prolaspe; uterine leiomyomas; septic abortions; and obstetric catastrophs.
What is pertuzumab hyaluronidase-zzxf used for?
Pertuzumab, trastuzumab, and hyaluronidase-zzxf is a fixed- dose combination of pertuzumab and trastuzumab that is given as a subcutaneous injection. It can be given in less time than pertuzumab or trastuzumab, which are given as infusions.
What types of cancers does pertuzumab treat?
The types of cancers pertuzumab is used to treat are tumors that produce more than the normal amount of a certain substance called HER2 protein.This medication is called a monoclonal antibody. It works by attaching to the HER2 cancer cells and blocking them from dividing and growing.